Search

Your search keyword '"Naproxen administration & dosage"' showing total 736 results

Search Constraints

Start Over You searched for: Descriptor "Naproxen administration & dosage" Remove constraint Descriptor: "Naproxen administration & dosage"
736 results on '"Naproxen administration & dosage"'

Search Results

151. Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.

152. Influence of drug property and product design on in vitro-in vivo correlation of complex modified-release dosage forms.

153. Naproxen in the horse: pharmacokinetics and side effects in the elderly.

154. The impact of liposomes on transdermal permeation of naproxen--in vitro studies.

155. SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.

156. Preparation and evaluation of microemulsion formulations of naproxen for dermal delivery.

157. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.

158. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.

159. Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap.

160. A case of seasonal recurrent myopericarditis.

161. Preparation and irradiation of Pluronic F127-based thermoreversible and mucoadhesive hydrogel for local delivery of naproxen.

162. Electrospun drug loaded membranes for sublingual administration of sumatriptan and naproxen.

163. A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury.

164. Naproxen with or without an antiemetic for acute migraine headaches in adults.

165. Design, development, and optimization of polymeric based-colonic drug delivery system of naproxen.

166. A phase 2 study of naproxen submicron particle capsules in patients with post-surgical dental pain.

167. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients.

168. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.

169. Increased gastric mucus secretion alleviates non-steroidal anti-inflammatory drug-induced abdominal pain.

170. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.

171. Prolonged naproxen joint residence time after intra-articular injection of lipophilic solutions comprising a naproxen glycolamide ester prodrug in the rat.

172. Mapping ion-induced mesophasic transformation in lyotropic in situ gelling system and its correlation with pharmaceutical performance.

173. Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function.

174. Comparative in vitro dissolution and in vivo bioavailability of diflunisal/naproxen fixed-dose combination tablets and concomitant administration of diflunisal and naproxen in healthy adult subjects.

175. No need for rescue medication (NNR) as an easily interpretable efficacy outcome measure in analgesic trials: validation in an individual-patient meta-analysis of dental pain placebo-controlled trials of naproxen.

176. Pain relievers: bad for your heart? People with heart disease should avoid prolonged use of certain anti-inflammatory drugs, Naproxen (Aleve) is safest.

177. Chitosan oligosaccharide as prospective cross-linking agent for naproxen-loaded Ca-alginate microparticles with improved pH sensitivity.

178. Modification of concomitant drug release from oil vehicles using drug-prodrug combinations to achieve sustained balanced analgesia after joint installation.

179. Reduced ulcerogenic potential and antiarthritic effect of chitosan-naproxen sodium complexes.

180. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base.

181. Novel brain targeting prodrugs of naproxen based on dimethylamino group with various linkages.

182. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine.

183. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.

184. Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen, and ibuprofen.

185. Preparation of high solubilizable microemulsion of naproxen and its solubilization mechanism.

186. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.

187. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.

188. Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery.

189. Naproxen glycine conjugate-synthesis, pharmaceutical preformulation and pharmacodynamic evaluation.

190. Kashin-Beck disease in Sichuan, China: report of a pilot open therapeutic trial.

191. Effects of three oral analgesics on postoperative pain following root canal preparation: a controlled clinical trial.

192. Inflammatory and noninflammatory arthropathy in patients with 18q deletion syndrome.

193. Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial.

194. Photosensitivity induced by naproxen.

195. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.

196. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.

197. Evaluation of the migraine treatment sumatriptan/naproxen sodium on blood pressure following long-term administration.

198. Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads.

199. Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs.

200. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents.

Catalog

Books, media, physical & digital resources